Weekly epoetin alfa during adjuvant chemotherapy for breast cancer

Effect on hemoglobin levels and quality of life

Clifford A. Hudis, Charles Vogel, Julie R. Gralow, Denise Williams, Martin Abrams, Jonathan Abramson, John Adams, Kent Adler, Mahmoud Afifi, Fakhiuddin Ahmed, Harish G. Ahuja, Judith A. Albro, Mitchell Alden, Michael Alexander, Mohammed Y. Ali, Ghassan Al-Jazayrly, Anderson M. Ambinder, V. C. Amin, John Anagnost, Michael Y. Ashigbi & 79 others Omar T. Atiq, Mary Lou Auchus, Craig J. Badolato, Thomas Baeker, Edward Balaban, Bruce Bank, Bharat H. Barai, Luis R. Barreras, Wilbur B. Bassett, Charles L. Beall, J. Thaddeus Beck, Elliot M. Belenkov, Donna A. Bell, Dan Ben-Zeev, Michael Berkovic, Dennis Berman, Utpal K. Bhanja, Karin Bigman, Roger T. Biss, Nanda Biswas, Kenneth Blankstein, Douglas Blayney, Virginia F. Borges, Linda D. Bosserman, Cordell J. Bott, Gino C. Bottino, L. Eamonn Boyle, Ranga Brahmamdam, Elizabeth J. Brate, William Brinkley, Katheleen Briscoe, Paula Broadway, Marcia J. Browne, Patricia Burns, Gary V. Burton, Atul Butala, Patricia Byrne, Vincent Caggiano, Elber Camacho, Laura C. Campbell, Luis Campos, Salvadore Caputto, Mark Carlson, Linda Carmosino, Jean M. Carrellas, Jennifer H. Caskey, William Cathcart-Rake, Majd Chahin, Kerry E. Chamberlain, Veena Charu, Sant P. Chawla, Alice P. Chen, David Chernicoff, Gurdeep Chhabra, Bernard Chinnasami, Jennifer Choate, Janak Choksi, Anthony Ciarolla, Patrick Cobb, Everardo Cobos, Paul Coluzzi, John D. Conroy, Javier Corral, John J. Costanzi, Mark Coughenour, Greenville Creekbaum, Jennie R. Crews, Edward B. Crowell, William Cunningham, Snehal A. Damle, Sheldon Davidson, Cathy Deen, Michael DeLeo, Salvatore A. DelPrete, Michael DeMattia, Eknath Deo, Francisco H. Dexeus, Robert F. Dobrzynski, Gary Dosik

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Anemia, fatigue, and diminished quality of life (QOL) often are associated with chemotherapy. In a previous study of patients with early-stage breast cancer and mean baseline hemoglobin (Hb) level of 12.1 g/dL, Hb decreased by 2.0 g/dL after 4 cyles of adjuvant chemotherapy. The current open-label, nonrandomized, multicenter, prospective, community-based study evaluated the effects of 12-24 weeks of epoetin alfa (40,000 U subcutaneously once weekly initiated at the start of start of standard adjuvant chemotherapy) in patients with stage I-III breast cancer and baseline Hb levels ≥ 10 g/dL to ≤ 14 g/dL on Hb level, transfusions, and QOL. Patients and methods: Of 1792 patients enrolled, 1785 were evaluable for safety and 1632 for efficacy. Mean age was 53 years ± 10.7 and mean baseline Hb level was 12.3 g/dL ± 1.0. From baseline levels, epoetin alfa significantly increased Hb (1.3 g/dL ± 1.5; P < 0.05) and improved QOL according to the Linear Analog Scale 26.7), and Functional Assessment of Cancer Therapy-Anemia (1.7 points ± 14.0; P < 0.05 in each case). Patients with baseline mild anemia (Hb level > 10 g/dL to ≤ 12 g/dL) also had significant improvements from baseline levels in all 3 LASA parameters (P < 0.05). Epoetin alfa was well tolerated, clinically relevant thrombovascular events were reported in 4.3 % of patients. Results: In this study, epoetin alfa significantly improved Hb and QOL in mildly anemic patients with early-stage breast cancer receiving adjuvant chemotherapy. However, based on recent studies showing an increased risk of thrombovascular events in patients with cancer treated with erythropoietic agents beyond correction of anemia, treatment with epoetin alfa is not indicated or recommended in patients with cancer and Hb levels > 12 g/dL. Conclusion: Controlled studies are warranted to confirm the safety and efficacy of epoetin alfa therapy in patients with mild anemia receiving chemotherapy.

Original languageEnglish
Pages (from-to)132-142
Number of pages11
JournalClinical Breast Cancer
Volume6
Issue number2
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Epoetin Alfa
Adjuvant Chemotherapy
Hemoglobins
Quality of Life
Breast Neoplasms
Anemia
Safety
Drug Therapy
Fatigue

Keywords

  • Anemia
  • Fatigue
  • Functional assessment of cancer therapy-anemia scale
  • Linear analog scale assessment
  • Transfusion reductions

ASJC Scopus subject areas

  • Cancer Research

Cite this

Hudis, C. A., Vogel, C., Gralow, J. R., Williams, D., Abrams, M., Abramson, J., ... Dosik, G. (2005). Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: Effect on hemoglobin levels and quality of life. Clinical Breast Cancer, 6(2), 132-142.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer : Effect on hemoglobin levels and quality of life. / Hudis, Clifford A.; Vogel, Charles; Gralow, Julie R.; Williams, Denise; Abrams, Martin; Abramson, Jonathan; Adams, John; Adler, Kent; Afifi, Mahmoud; Ahmed, Fakhiuddin; Ahuja, Harish G.; Albro, Judith A.; Alden, Mitchell; Alexander, Michael; Ali, Mohammed Y.; Al-Jazayrly, Ghassan; Ambinder, Anderson M.; Amin, V. C.; Anagnost, John; Ashigbi, Michael Y.; Atiq, Omar T.; Auchus, Mary Lou; Badolato, Craig J.; Baeker, Thomas; Balaban, Edward; Bank, Bruce; Barai, Bharat H.; Barreras, Luis R.; Bassett, Wilbur B.; Beall, Charles L.; Beck, J. Thaddeus; Belenkov, Elliot M.; Bell, Donna A.; Ben-Zeev, Dan; Berkovic, Michael; Berman, Dennis; Bhanja, Utpal K.; Bigman, Karin; Biss, Roger T.; Biswas, Nanda; Blankstein, Kenneth; Blayney, Douglas; Borges, Virginia F.; Bosserman, Linda D.; Bott, Cordell J.; Bottino, Gino C.; Boyle, L. Eamonn; Brahmamdam, Ranga; Brate, Elizabeth J.; Brinkley, William; Briscoe, Katheleen; Broadway, Paula; Browne, Marcia J.; Burns, Patricia; Burton, Gary V.; Butala, Atul; Byrne, Patricia; Caggiano, Vincent; Camacho, Elber; Campbell, Laura C.; Campos, Luis; Caputto, Salvadore; Carlson, Mark; Carmosino, Linda; Carrellas, Jean M.; Caskey, Jennifer H.; Cathcart-Rake, William; Chahin, Majd; Chamberlain, Kerry E.; Charu, Veena; Chawla, Sant P.; Chen, Alice P.; Chernicoff, David; Chhabra, Gurdeep; Chinnasami, Bernard; Choate, Jennifer; Choksi, Janak; Ciarolla, Anthony; Cobb, Patrick; Cobos, Everardo; Coluzzi, Paul; Conroy, John D.; Corral, Javier; Costanzi, John J.; Coughenour, Mark; Creekbaum, Greenville; Crews, Jennie R.; Crowell, Edward B.; Cunningham, William; Damle, Snehal A.; Davidson, Sheldon; Deen, Cathy; DeLeo, Michael; DelPrete, Salvatore A.; DeMattia, Michael; Deo, Eknath; Dexeus, Francisco H.; Dobrzynski, Robert F.; Dosik, Gary.

In: Clinical Breast Cancer, Vol. 6, No. 2, 01.01.2005, p. 132-142.

Research output: Contribution to journalArticle

Hudis, CA, Vogel, C, Gralow, JR, Williams, D, Abrams, M, Abramson, J, Adams, J, Adler, K, Afifi, M, Ahmed, F, Ahuja, HG, Albro, JA, Alden, M, Alexander, M, Ali, MY, Al-Jazayrly, G, Ambinder, AM, Amin, VC, Anagnost, J, Ashigbi, MY, Atiq, OT, Auchus, ML, Badolato, CJ, Baeker, T, Balaban, E, Bank, B, Barai, BH, Barreras, LR, Bassett, WB, Beall, CL, Beck, JT, Belenkov, EM, Bell, DA, Ben-Zeev, D, Berkovic, M, Berman, D, Bhanja, UK, Bigman, K, Biss, RT, Biswas, N, Blankstein, K, Blayney, D, Borges, VF, Bosserman, LD, Bott, CJ, Bottino, GC, Boyle, LE, Brahmamdam, R, Brate, EJ, Brinkley, W, Briscoe, K, Broadway, P, Browne, MJ, Burns, P, Burton, GV, Butala, A, Byrne, P, Caggiano, V, Camacho, E, Campbell, LC, Campos, L, Caputto, S, Carlson, M, Carmosino, L, Carrellas, JM, Caskey, JH, Cathcart-Rake, W, Chahin, M, Chamberlain, KE, Charu, V, Chawla, SP, Chen, AP, Chernicoff, D, Chhabra, G, Chinnasami, B, Choate, J, Choksi, J, Ciarolla, A, Cobb, P, Cobos, E, Coluzzi, P, Conroy, JD, Corral, J, Costanzi, JJ, Coughenour, M, Creekbaum, G, Crews, JR, Crowell, EB, Cunningham, W, Damle, SA, Davidson, S, Deen, C, DeLeo, M, DelPrete, SA, DeMattia, M, Deo, E, Dexeus, FH, Dobrzynski, RF & Dosik, G 2005, 'Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: Effect on hemoglobin levels and quality of life', Clinical Breast Cancer, vol. 6, no. 2, pp. 132-142.
Hudis, Clifford A. ; Vogel, Charles ; Gralow, Julie R. ; Williams, Denise ; Abrams, Martin ; Abramson, Jonathan ; Adams, John ; Adler, Kent ; Afifi, Mahmoud ; Ahmed, Fakhiuddin ; Ahuja, Harish G. ; Albro, Judith A. ; Alden, Mitchell ; Alexander, Michael ; Ali, Mohammed Y. ; Al-Jazayrly, Ghassan ; Ambinder, Anderson M. ; Amin, V. C. ; Anagnost, John ; Ashigbi, Michael Y. ; Atiq, Omar T. ; Auchus, Mary Lou ; Badolato, Craig J. ; Baeker, Thomas ; Balaban, Edward ; Bank, Bruce ; Barai, Bharat H. ; Barreras, Luis R. ; Bassett, Wilbur B. ; Beall, Charles L. ; Beck, J. Thaddeus ; Belenkov, Elliot M. ; Bell, Donna A. ; Ben-Zeev, Dan ; Berkovic, Michael ; Berman, Dennis ; Bhanja, Utpal K. ; Bigman, Karin ; Biss, Roger T. ; Biswas, Nanda ; Blankstein, Kenneth ; Blayney, Douglas ; Borges, Virginia F. ; Bosserman, Linda D. ; Bott, Cordell J. ; Bottino, Gino C. ; Boyle, L. Eamonn ; Brahmamdam, Ranga ; Brate, Elizabeth J. ; Brinkley, William ; Briscoe, Katheleen ; Broadway, Paula ; Browne, Marcia J. ; Burns, Patricia ; Burton, Gary V. ; Butala, Atul ; Byrne, Patricia ; Caggiano, Vincent ; Camacho, Elber ; Campbell, Laura C. ; Campos, Luis ; Caputto, Salvadore ; Carlson, Mark ; Carmosino, Linda ; Carrellas, Jean M. ; Caskey, Jennifer H. ; Cathcart-Rake, William ; Chahin, Majd ; Chamberlain, Kerry E. ; Charu, Veena ; Chawla, Sant P. ; Chen, Alice P. ; Chernicoff, David ; Chhabra, Gurdeep ; Chinnasami, Bernard ; Choate, Jennifer ; Choksi, Janak ; Ciarolla, Anthony ; Cobb, Patrick ; Cobos, Everardo ; Coluzzi, Paul ; Conroy, John D. ; Corral, Javier ; Costanzi, John J. ; Coughenour, Mark ; Creekbaum, Greenville ; Crews, Jennie R. ; Crowell, Edward B. ; Cunningham, William ; Damle, Snehal A. ; Davidson, Sheldon ; Deen, Cathy ; DeLeo, Michael ; DelPrete, Salvatore A. ; DeMattia, Michael ; Deo, Eknath ; Dexeus, Francisco H. ; Dobrzynski, Robert F. ; Dosik, Gary. / Weekly epoetin alfa during adjuvant chemotherapy for breast cancer : Effect on hemoglobin levels and quality of life. In: Clinical Breast Cancer. 2005 ; Vol. 6, No. 2. pp. 132-142.
@article{288a5fa1e5774db4b3cf140608d16e2f,
title = "Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: Effect on hemoglobin levels and quality of life",
abstract = "Purpose: Anemia, fatigue, and diminished quality of life (QOL) often are associated with chemotherapy. In a previous study of patients with early-stage breast cancer and mean baseline hemoglobin (Hb) level of 12.1 g/dL, Hb decreased by 2.0 g/dL after 4 cyles of adjuvant chemotherapy. The current open-label, nonrandomized, multicenter, prospective, community-based study evaluated the effects of 12-24 weeks of epoetin alfa (40,000 U subcutaneously once weekly initiated at the start of start of standard adjuvant chemotherapy) in patients with stage I-III breast cancer and baseline Hb levels ≥ 10 g/dL to ≤ 14 g/dL on Hb level, transfusions, and QOL. Patients and methods: Of 1792 patients enrolled, 1785 were evaluable for safety and 1632 for efficacy. Mean age was 53 years ± 10.7 and mean baseline Hb level was 12.3 g/dL ± 1.0. From baseline levels, epoetin alfa significantly increased Hb (1.3 g/dL ± 1.5; P < 0.05) and improved QOL according to the Linear Analog Scale 26.7), and Functional Assessment of Cancer Therapy-Anemia (1.7 points ± 14.0; P < 0.05 in each case). Patients with baseline mild anemia (Hb level > 10 g/dL to ≤ 12 g/dL) also had significant improvements from baseline levels in all 3 LASA parameters (P < 0.05). Epoetin alfa was well tolerated, clinically relevant thrombovascular events were reported in 4.3 {\%} of patients. Results: In this study, epoetin alfa significantly improved Hb and QOL in mildly anemic patients with early-stage breast cancer receiving adjuvant chemotherapy. However, based on recent studies showing an increased risk of thrombovascular events in patients with cancer treated with erythropoietic agents beyond correction of anemia, treatment with epoetin alfa is not indicated or recommended in patients with cancer and Hb levels > 12 g/dL. Conclusion: Controlled studies are warranted to confirm the safety and efficacy of epoetin alfa therapy in patients with mild anemia receiving chemotherapy.",
keywords = "Anemia, Fatigue, Functional assessment of cancer therapy-anemia scale, Linear analog scale assessment, Transfusion reductions",
author = "Hudis, {Clifford A.} and Charles Vogel and Gralow, {Julie R.} and Denise Williams and Martin Abrams and Jonathan Abramson and John Adams and Kent Adler and Mahmoud Afifi and Fakhiuddin Ahmed and Ahuja, {Harish G.} and Albro, {Judith A.} and Mitchell Alden and Michael Alexander and Ali, {Mohammed Y.} and Ghassan Al-Jazayrly and Ambinder, {Anderson M.} and Amin, {V. C.} and John Anagnost and Ashigbi, {Michael Y.} and Atiq, {Omar T.} and Auchus, {Mary Lou} and Badolato, {Craig J.} and Thomas Baeker and Edward Balaban and Bruce Bank and Barai, {Bharat H.} and Barreras, {Luis R.} and Bassett, {Wilbur B.} and Beall, {Charles L.} and Beck, {J. Thaddeus} and Belenkov, {Elliot M.} and Bell, {Donna A.} and Dan Ben-Zeev and Michael Berkovic and Dennis Berman and Bhanja, {Utpal K.} and Karin Bigman and Biss, {Roger T.} and Nanda Biswas and Kenneth Blankstein and Douglas Blayney and Borges, {Virginia F.} and Bosserman, {Linda D.} and Bott, {Cordell J.} and Bottino, {Gino C.} and Boyle, {L. Eamonn} and Ranga Brahmamdam and Brate, {Elizabeth J.} and William Brinkley and Katheleen Briscoe and Paula Broadway and Browne, {Marcia J.} and Patricia Burns and Burton, {Gary V.} and Atul Butala and Patricia Byrne and Vincent Caggiano and Elber Camacho and Campbell, {Laura C.} and Luis Campos and Salvadore Caputto and Mark Carlson and Linda Carmosino and Carrellas, {Jean M.} and Caskey, {Jennifer H.} and William Cathcart-Rake and Majd Chahin and Chamberlain, {Kerry E.} and Veena Charu and Chawla, {Sant P.} and Chen, {Alice P.} and David Chernicoff and Gurdeep Chhabra and Bernard Chinnasami and Jennifer Choate and Janak Choksi and Anthony Ciarolla and Patrick Cobb and Everardo Cobos and Paul Coluzzi and Conroy, {John D.} and Javier Corral and Costanzi, {John J.} and Mark Coughenour and Greenville Creekbaum and Crews, {Jennie R.} and Crowell, {Edward B.} and William Cunningham and Damle, {Snehal A.} and Sheldon Davidson and Cathy Deen and Michael DeLeo and DelPrete, {Salvatore A.} and Michael DeMattia and Eknath Deo and Dexeus, {Francisco H.} and Dobrzynski, {Robert F.} and Gary Dosik",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "132--142",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Weekly epoetin alfa during adjuvant chemotherapy for breast cancer

T2 - Effect on hemoglobin levels and quality of life

AU - Hudis, Clifford A.

AU - Vogel, Charles

AU - Gralow, Julie R.

AU - Williams, Denise

AU - Abrams, Martin

AU - Abramson, Jonathan

AU - Adams, John

AU - Adler, Kent

AU - Afifi, Mahmoud

AU - Ahmed, Fakhiuddin

AU - Ahuja, Harish G.

AU - Albro, Judith A.

AU - Alden, Mitchell

AU - Alexander, Michael

AU - Ali, Mohammed Y.

AU - Al-Jazayrly, Ghassan

AU - Ambinder, Anderson M.

AU - Amin, V. C.

AU - Anagnost, John

AU - Ashigbi, Michael Y.

AU - Atiq, Omar T.

AU - Auchus, Mary Lou

AU - Badolato, Craig J.

AU - Baeker, Thomas

AU - Balaban, Edward

AU - Bank, Bruce

AU - Barai, Bharat H.

AU - Barreras, Luis R.

AU - Bassett, Wilbur B.

AU - Beall, Charles L.

AU - Beck, J. Thaddeus

AU - Belenkov, Elliot M.

AU - Bell, Donna A.

AU - Ben-Zeev, Dan

AU - Berkovic, Michael

AU - Berman, Dennis

AU - Bhanja, Utpal K.

AU - Bigman, Karin

AU - Biss, Roger T.

AU - Biswas, Nanda

AU - Blankstein, Kenneth

AU - Blayney, Douglas

AU - Borges, Virginia F.

AU - Bosserman, Linda D.

AU - Bott, Cordell J.

AU - Bottino, Gino C.

AU - Boyle, L. Eamonn

AU - Brahmamdam, Ranga

AU - Brate, Elizabeth J.

AU - Brinkley, William

AU - Briscoe, Katheleen

AU - Broadway, Paula

AU - Browne, Marcia J.

AU - Burns, Patricia

AU - Burton, Gary V.

AU - Butala, Atul

AU - Byrne, Patricia

AU - Caggiano, Vincent

AU - Camacho, Elber

AU - Campbell, Laura C.

AU - Campos, Luis

AU - Caputto, Salvadore

AU - Carlson, Mark

AU - Carmosino, Linda

AU - Carrellas, Jean M.

AU - Caskey, Jennifer H.

AU - Cathcart-Rake, William

AU - Chahin, Majd

AU - Chamberlain, Kerry E.

AU - Charu, Veena

AU - Chawla, Sant P.

AU - Chen, Alice P.

AU - Chernicoff, David

AU - Chhabra, Gurdeep

AU - Chinnasami, Bernard

AU - Choate, Jennifer

AU - Choksi, Janak

AU - Ciarolla, Anthony

AU - Cobb, Patrick

AU - Cobos, Everardo

AU - Coluzzi, Paul

AU - Conroy, John D.

AU - Corral, Javier

AU - Costanzi, John J.

AU - Coughenour, Mark

AU - Creekbaum, Greenville

AU - Crews, Jennie R.

AU - Crowell, Edward B.

AU - Cunningham, William

AU - Damle, Snehal A.

AU - Davidson, Sheldon

AU - Deen, Cathy

AU - DeLeo, Michael

AU - DelPrete, Salvatore A.

AU - DeMattia, Michael

AU - Deo, Eknath

AU - Dexeus, Francisco H.

AU - Dobrzynski, Robert F.

AU - Dosik, Gary

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: Anemia, fatigue, and diminished quality of life (QOL) often are associated with chemotherapy. In a previous study of patients with early-stage breast cancer and mean baseline hemoglobin (Hb) level of 12.1 g/dL, Hb decreased by 2.0 g/dL after 4 cyles of adjuvant chemotherapy. The current open-label, nonrandomized, multicenter, prospective, community-based study evaluated the effects of 12-24 weeks of epoetin alfa (40,000 U subcutaneously once weekly initiated at the start of start of standard adjuvant chemotherapy) in patients with stage I-III breast cancer and baseline Hb levels ≥ 10 g/dL to ≤ 14 g/dL on Hb level, transfusions, and QOL. Patients and methods: Of 1792 patients enrolled, 1785 were evaluable for safety and 1632 for efficacy. Mean age was 53 years ± 10.7 and mean baseline Hb level was 12.3 g/dL ± 1.0. From baseline levels, epoetin alfa significantly increased Hb (1.3 g/dL ± 1.5; P < 0.05) and improved QOL according to the Linear Analog Scale 26.7), and Functional Assessment of Cancer Therapy-Anemia (1.7 points ± 14.0; P < 0.05 in each case). Patients with baseline mild anemia (Hb level > 10 g/dL to ≤ 12 g/dL) also had significant improvements from baseline levels in all 3 LASA parameters (P < 0.05). Epoetin alfa was well tolerated, clinically relevant thrombovascular events were reported in 4.3 % of patients. Results: In this study, epoetin alfa significantly improved Hb and QOL in mildly anemic patients with early-stage breast cancer receiving adjuvant chemotherapy. However, based on recent studies showing an increased risk of thrombovascular events in patients with cancer treated with erythropoietic agents beyond correction of anemia, treatment with epoetin alfa is not indicated or recommended in patients with cancer and Hb levels > 12 g/dL. Conclusion: Controlled studies are warranted to confirm the safety and efficacy of epoetin alfa therapy in patients with mild anemia receiving chemotherapy.

AB - Purpose: Anemia, fatigue, and diminished quality of life (QOL) often are associated with chemotherapy. In a previous study of patients with early-stage breast cancer and mean baseline hemoglobin (Hb) level of 12.1 g/dL, Hb decreased by 2.0 g/dL after 4 cyles of adjuvant chemotherapy. The current open-label, nonrandomized, multicenter, prospective, community-based study evaluated the effects of 12-24 weeks of epoetin alfa (40,000 U subcutaneously once weekly initiated at the start of start of standard adjuvant chemotherapy) in patients with stage I-III breast cancer and baseline Hb levels ≥ 10 g/dL to ≤ 14 g/dL on Hb level, transfusions, and QOL. Patients and methods: Of 1792 patients enrolled, 1785 were evaluable for safety and 1632 for efficacy. Mean age was 53 years ± 10.7 and mean baseline Hb level was 12.3 g/dL ± 1.0. From baseline levels, epoetin alfa significantly increased Hb (1.3 g/dL ± 1.5; P < 0.05) and improved QOL according to the Linear Analog Scale 26.7), and Functional Assessment of Cancer Therapy-Anemia (1.7 points ± 14.0; P < 0.05 in each case). Patients with baseline mild anemia (Hb level > 10 g/dL to ≤ 12 g/dL) also had significant improvements from baseline levels in all 3 LASA parameters (P < 0.05). Epoetin alfa was well tolerated, clinically relevant thrombovascular events were reported in 4.3 % of patients. Results: In this study, epoetin alfa significantly improved Hb and QOL in mildly anemic patients with early-stage breast cancer receiving adjuvant chemotherapy. However, based on recent studies showing an increased risk of thrombovascular events in patients with cancer treated with erythropoietic agents beyond correction of anemia, treatment with epoetin alfa is not indicated or recommended in patients with cancer and Hb levels > 12 g/dL. Conclusion: Controlled studies are warranted to confirm the safety and efficacy of epoetin alfa therapy in patients with mild anemia receiving chemotherapy.

KW - Anemia

KW - Fatigue

KW - Functional assessment of cancer therapy-anemia scale

KW - Linear analog scale assessment

KW - Transfusion reductions

UR - http://www.scopus.com/inward/record.url?scp=22144449587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144449587&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 132

EP - 142

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -